[40]Pusic I,Choi J,Fiala MA,et Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome[J].Biol Blood Marrow Transplant,2015,21(10)::10.1016/

[41]Gao L,Zhang Y,Wang S,et of rhG-CSF Combined With Decitabine Prophylaxis on Relapse of Patients With High-Risk MRD-Negative AML After HSCT:An Open-Label,Multicenter,Randomized Controlled Trial[J].J Clin Oncol,2020.DOI:10.1200/

[42]Andreani G,Dragani M,Serra A,et plus decitabine induced complete remission with molecular response in acute myeloid leukemia relapsed after hematopoietic stem cell transplantation[J].Am J Hematol,2019,94(2)::10.1002/ajh..

[43]Kalin B,Van Norden Y,Van Gelder M,et and decitabine prior to donor lymphocyte infusion in allogeneic stem celltransplantation[J].Blood advances,2020,4(18)::10.1182/bloodadvances..

[44]Bug G,Burchert A,Wagner EM,et al.Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML(PANOBESTtrial)[J].Leukemia,2017,31(11)::10.1038/

[45]Schmid C,Labopin M,Nagler A,et ,risk factors,and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation[J].Blood,2012,119(6)::10.1182/blood-2011-08-.

[46]Yan CH,Wang JZ,Liu DH,et followed by modified donor lymphocyte infusion as a treatment for relapsed acute leukemia after haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion:superior outcomes compared with chemotherapy alone and an analysis of prognostic factors[J].Eur J Haematol,2013,91(4)::10.1111/ejh..

[47]Tischer J,Engel N,Fritsch S,et haematopoietic SCT using HLA-haploidentical donors in patients with relapse of acute leukaemia after a first allogeneic transplantation[J].Bone MarrowTransplant,2014,49(7)::10.1038/

[48]Leung AY,Tse E,Hwang YY,et treatment of leukemia relapses after allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning second transplantation from the originaldonor[J].Am J Hematol,2013,88(6)::10.1002/ajh..

[49]Shimoni A,Labopin M,Finke J,et al.Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant:a study of the Acute Leukemia Working Party of EBMT[J].Blood Cancer J,2019,9(12):88.DOI:10.1038/s-019-0251-3.

[50]Imus PH,Blackford AL,Bettinotti M,et al.Major Histocompatibility Mismatch and Donor Choice for Second Allogeneic Bone Marrow Transplantation[J].Biol Blood Marrow Transplant,2017,23(11)::10.1016/

[51]Orti G,Sanz J,Bermudez A,et of Second Allogeneic Hematopoietic Cell Transplantation afterRelapse of Myeloid Malignancies following Allogeneic Hematopoietic Cell Transplantation:A Retrospective Cohort on Behalf of the Grupo Espanol de Trasplante Hematopoyetico[J].Biol Blood Marrow Transplant,2016,22(3)::10.1016/

[52]Park JH,Riviere I,Gonen M,et Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia[J].N EnglJ Med,2018,378(5)::10.1056/NEJMoa.

[53]Hu Y,Wu Z,Luo Y,et Anti-leukemia Activities of Chimeric Antigen Receptor-Modified T Cells against CD19 in Chinese Patients with Relapsed/Refractory Acute Lymphocytic Leukemia[J].Clin Cancer Res,2017,23(13)::10.1158/

[54]Zhao H,Wei J,Wei G,et MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia:a multi-center retrospective study[J].J Hematol Oncol,2020,13(1):42.DOI:10.1186/s-020-00873-7.

[55]Zhang Y,Chen H,Song Y,et antigens receptor T cell therapy as a bridge to haematopoietic stem cell transplantation for refractory/relapsed B-cell acute lymphomalastic leukemia[J].Br J Haematol,2020,189(1)::10.1111/bjh..

[56]Cheng Y,Chen Y,Yan C,et CD19-Targeted T Cell Infusion Eliminates B Cell Acute Lymphoblastic Leukemia Minimal Residual Disease with No Response to Donor Lymphocytes after Allogeneic Hematopoietic Stem Cell Transplantation[J].Engineering,2019,5(1)::10.1016/

[57]Chen Y,Cheng Y,Suo P,et CD19-targeted T cell infusion inducesminimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation[J].Br J Haematol,2017,179(4)::10.1111/bjh..

[58]Zhang C,Wang XQ,Zhang RL,et CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant[J].Leukemia,2020.DOI:10.1038/s-020-01056-6.

[59]Jia H,Wang Z,Wang Y,et CD19/CD22 bispecific CAR-T cellsinduced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation[J].J Hematol Oncol,2019,12(1):57.DOI:10.1186/s-019-0741-6.

[60]Yoon JH,Min GJ,Park SS,et outcome of blinatumomab followed by allogeneic hematopoietic cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage[J].Cancer Med,2019,8(18)::10.1002/

文章来源：《中国实验血液学杂志》 网址: http://www.zgsyxyxzz.cn/qikandaodu/2021/0508/635.html